

03. Streamlining treatment for drug-resistant TB: market approaches for better TB care

Thursday, 30 October 2014, 17:00 - 18:30

Room 114



Type Sponsored Satellite Symposium

Track Tuberculosis

Topic Medical management of TB and drug resistant TB

Organised by UNITAID

Description A wide range of treatment options exist with the use of around 20 drug-resistant TB medicines. While some variation is vital, other options may be clinically unnecessary. This complicates TB care and fragments an already small market, leading to supply shortages and high prices. Simpler, shorter TB treatment could foster healthier markets, better enabling appropriate TB medicines to be provided to people who urgently need them. But evidence is needed to inform effective use of new and existing medicines. This session will explore market trends and potential impact of streamlining drug-resistant TB treatment.

Target audience Many stakeholders have an interest in understanding needs and likely evolution of TB medicines markets, including implementers, governments, donors, international organisations, regulators, policy-makers, civil society, academics, and industry.

Objectives

1. Review the urgent need for shorter, safer, effective drug-resistant TB treatment
2. Examine the TB landscape to understand the potential impact of streamlined treatment
3. Describe tangible first steps in transforming markets for drug-resistant TB treatment
4. Discuss further strategies to improve drug-resistant TB care through market approaches

Keywords Access; MDR-TB; medicines; innovation; markets; tuberculosis

Coordinator(s) Janet Ginnard (Switzerland), Katherine Blumer (Switzerland)

Chair(s) Brenda Waning (Switzerland), Carol Nawina Nyirenda (Zambia)

Presentations

17:00 - 17:15 Perspectives from the community: the need for shorter, safer effective drug-resistant TB treatment
Dalene Von Delft (South Africa), Thato Mosidi (South Africa)

17:20 - 17:35 Insights from the TB medicines landscape: pre-conditions for new drugs impact
Carmen Perez Casas (Switzerland)

17:40 - 17:55 Priority drug-resistant TB regimens: improving the knowledge base to transform the market
Michael Rich (USA)

18:00 - 18:15 Further strategies to consolidate demand: addressing non-essential variation and other opportunities
Regina Osih (South Africa)

18:20 - 18:30 Discussion